NAME,DESCRIPTION,SEQAPASS,GENE_SYMBOLS,GENE_NAMES,GENE_URLS,AOP,EVENT,HIT_CALL,TOP,SCALED_TOP,AC50,LOGAC50,BMAD,MAXMED,MAXMED_UNITS,MAXMEDCONC,CUTOFF,FLAGS,MODLACC,MODLAC10,MODLACB,STOCK_CONCENTRATION,INTENDED_TARGET_FAMILY
ACEA_AR_agonist_AUC_viability,"Data from the assay component ACEA_AR_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,197.010483361756,7.332146736482977,84.85280022438727,1.92866617902768,8.95647120560566,155.284601428343,percent_activity,2,26.869413616817,"[""Noisy data"",""Noisy data""]",1.82847204002158,1.82847204002158,1.80938554663393,20,cell cycle
ACEA_AR_antagonist_80hr,"Data from the assay component ACEA_AR_antagonist_80hr was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, measures of the cells for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",, , , ,,,Active,3.43183827920416,9.375372733406234,64.503462351497,1.80958302688011,0.122016065451132,2.85986524216955,log2_fold_induction,2,0.366048196353396,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.55811928289746,1.55811928289746,1.54960868579802,20,nuclear receptor
ACEA_AR_antagonist_AUC_viability,"Data from the assay component ACEA_AR_antagonist_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,166.066259895665,5.7361577214312,53.05443084866396,1.72472165992009,9.65026114229828,136.620892945289,percent_activity,2,28.9507834268948,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.44427533932844,1.44427533932844,1.32850691742884,20,cell cycle
APR_HepG2_CellCycleArrest_72h_dn,"Data from the assay component APR_HepG2_CellCycleArrest_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellCycleArrest_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",, , , ,,,Active,1.27483271797842,1.3748165018299092,107.86003561698192,2.03286055936264,0.0927274815425616,1.06236059838495,log2_fold_induction,2.30102999566398,0.927274815425616,"[""Borderline active"",""Borderline active""]",2.22137512833138,1.78771315630382,1.61076644905294,20,cell cycle
APR_HepG2_CellLoss_72h_dn,"Data from the assay component APR_HepG2_CellLoss_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.22182426823245,1.3768905548778063,101.27852381484811,2.00551736266007,0.0887379366431112,1.07139821860135,log2_fold_induction,2.30102999566398,0.887379366431112,,2.15343439144121,1.81178364784006,1.67245035629284,20,cell cycle
ATG_AP_1_CIS_up,"Data from the assay component ATG_AP_1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_AP_1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOS and JUN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.","NP_005243.1|NP_002219.1", , , ,,,Active,1.1964076845931075,1.994697165292747,42.718470619903776,1.6306156959580926,0.11995882938125292,1.195087299442531,log2_fold_induction,2,0.5997941469062646,"[""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active""]",1.6309043429037708,1.5848235049829138,1.5113324973790934,20,dna binding
ATG_BRE_CIS_up,"Data from the assay component ATG_BRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_BRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SMAD1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is Smad protein.",NP_005891.1, , , ,,,Active,1.4567338479445602,1.5906410247942762,19.122813749470122,1.2815517951556195,0.183163117917566,1.2139448733195726,log2_fold_induction,2,0.91581558958783,"[""Hit-call potentially confounded by overfitting""]",1.6847642580496698,0.8975786823925462,-0.40101137039471224,20,dna binding
ATG_C_EBP_CIS_up,"Data from the assay component ATG_C_EBP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_C_EBP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CEBPB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_005185.2, , , ,,,Active,0.6888713682016481,1.378504604743378,6.987618880189152,0.8443292095987334,0.09994473226005482,0.6299116908679145,log2_fold_induction,2,0.4997236613002741,,1.331824231022403,0.7136424063478803,-0.2581990761285995,20,dna binding
ATG_chAR_XSP2_dn,ATG_chAR_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,, , , ,,,Active,1.7849430101373038,2.8298135935322124,81.4596789057831,1.910942693870266,0.21025448628099835,1.7835881421872586,log2_fold_induction,2.30102999566398,0.6307634588429951,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.878141820695818,1.878141820695818,1.7916623184664817,20,nuclear receptor
ATG_chAR_XSP2_dn,ATG_chAR_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,, , , ,,,Active,1.7849430101373038,2.8298135935322124,81.4596789057831,1.910942693870266,0.21025448628099835,1.7835881421872586,log2_fold_induction,2.30102999566398,0.6307634588429951,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.878141820695818,1.878141820695818,1.7916623184664817,20,nuclear receptor
ATG_chERa_XSP2_up,"The assay endpoint ATG_chERa_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",, , , ,,,Active,1.1491374953699296,1.4872846015820713,8.27564449875921,0.9178018261764795,0.2575470971611746,0.9576145797160687,log2_fold_induction,1.30102999566398,0.7726412914835237,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",0.9568290887963417,0.9568290887963417,0.7985212111981723,20,nuclear receptor
ATG_CRE_CIS_up,"Data from the assay component ATG_CRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_CRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CREB3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_006359.3, , , ,,,Active,1.1811939997641119,1.6168747732475217,21.34630855656693,1.3293227827744087,0.14610828486013952,0.9843283331445102,log2_fold_induction,2,0.7305414243006976,,1.5753269872352682,1.0606728732466424,0.21042705199140177,20,dna binding
ATG_EGR_CIS_up,"Data from the assay component ATG_EGR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_EGR_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene EGR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_001955.1, , , ,,,Active,1.0874262558372154,1.5586556666843552,25.236455984723268,1.4020283658515584,0.13953386614895374,0.9375671939495189,log2_fold_induction,2,0.6976693307447688,"[""Hit-call potentially confounded by overfitting""]",1.5901111170197015,1.2506496589936873,0.6922302817628012,20,dna binding
ATG_ERa_TRANS_up,"Data from the assay component ATG_ERa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2, , , ,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,2.641818430422247,2.3904546727882474,39.191680643419,1.5931938875789649,0.22103062321117403,2.325502052085856,log2_fold_induction,2,1.10515311605587,,1.5259374195364164,1.370122573454584,1.1448815144933104,20,nuclear receptor
ATG_frAR_XSP2_dn,"The assay endpoint ATG_frAR_XSP2_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",, , , ,,,Active,2.06260302911238,3.607933738740368,101.51652423243154,2.0065367397750187,0.1905617987534044,1.7188358577270038,log2_fold_induction,2.30102999566398,0.5716853962602132,"[""Hit-call potentially confounded by overfitting""]",1.826163450509059,1.826163450509059,1.5930818144006418,20,nuclear receptor
ATG_frAR_XSP2_dn,"The assay endpoint ATG_frAR_XSP2_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",, , , ,,,Active,2.06260302911238,3.607933738740368,101.51652423243154,2.0065367397750187,0.1905617987534044,1.7188358577270038,log2_fold_induction,2.30102999566398,0.5716853962602132,"[""Hit-call potentially confounded by overfitting""]",1.826163450509059,1.826163450509059,1.5930818144006418,20,nuclear receptor
ATG_frER1_XSP2_up,"The assay endpoint ATG_frER1_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",, , , ,,,Active,1.367166334062123,1.8066582563357347,28.292995802700656,1.4516789351451478,0.25224588532771924,1.2710717248992118,log2_fold_induction,2.30102999566398,0.7567376559831578,,1.5204153526022086,1.5204153526022086,0.7487433596480484,20,nuclear receptor
ATG_hAR_XSP2_dn,ATG_hAR_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,, , , ,,,Active,1.4382177354044108,2.12086598972043,7.175030270653206,0.8558237376499211,0.2260425289127603,1.391951421198139,log2_fold_induction,2.30102999566398,0.6781275867382809,,0.8086161252053935,0.8086161252053935,-0.05324093712500644,20,nuclear receptor
ATG_hAR_XSP2_dn,ATG_hAR_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,, , , ,,,Active,1.4382177354044108,2.12086598972043,7.175030270653206,0.8558237376499211,0.2260425289127603,1.391951421198139,log2_fold_induction,2.30102999566398,0.6781275867382809,,0.8086161252053935,0.8086161252053935,-0.05324093712500644,20,nuclear receptor
ATG_hERa_XSP2_up,"The assay endpoint ATG_hERa_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2, , , ,,,Active,1.1856265747376504,1.8964352712280288,22.60567338481123,1.3542174484617493,0.20839564853166204,1.1699279185736986,log2_fold_induction,2.30102999566398,0.6251869455949861,,1.379807512235285,1.379807512235285,0.8399255474296308,20,nuclear receptor
ATG_hPPARg_XSP2_up,"The assay endpoint ATG_hPPARg_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_056953.2, , , ,,,Active,1.1165157818820575,1.8084610513313992,21.173173973814663,1.325785966001957,0.20579482594884976,1.1495119687057171,log2_fold_induction,1.84509804001426,0.6173844778465493,"[""Hit-call potentially confounded by overfitting""]",1.3373285782478774,1.3373285782478774,1.206505652310363,20,nuclear receptor
ATG_IR1_CIS_up,"Data from the assay component ATG_IR1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_IR1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_001193922.1, , , ,"[27,61,27,61]",[479],Active,0.6309898556896388,1.2880683172416099,32.00611677371668,1.5052329854202955,0.09797459455270192,0.601282961850814,log2_fold_induction,2,0.4898729727635096,"[""Only highest conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.7105506350462876,1.482638617681791,1.1427515858257835,20,nuclear receptor
ATG_mPPARg_XSP2_up,"The assay endpoint ATG_mPPARg_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",, , , ,,,Active,1.4295933785272483,2.731285318236067,40.026252184832494,1.602344927311052,0.17447138275671079,1.1913278154619191,log2_fold_induction,2.30102999566398,0.5234141482701323,,1.3514411862098992,1.3514411862098992,0.5979216550264905,20,nuclear receptor
ATG_MRE_CIS_up,"Data from the assay component ATG_MRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_MRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MTF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_005946.2, , , ,,,Active,1.215937517974385,2.021737198301881,16.935257317136415,1.2287917997738853,0.12028640705584168,1.113416866718187,log2_fold_induction,2,0.6014320352792084,,1.2217605377310459,0.9467132476882829,0.5103656444556092,20,dna binding
ATG_NRF2_ARE_CIS_up,"Data from the assay component ATG_NRF2_ARE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NRF2_ARE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFE2L2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_006155.2, , , ,"[61,61]",[478],Active,2.7979338040657007,3.6028526176551496,26.87955073431634,1.4294220056303784,0.15531769411576343,2.3316115034137384,log2_fold_induction,2,0.7765884705788172,,1.083862017484229,0.8476938882906848,0.6357082842871145,20,dna binding
ATG_Oct_MLP_CIS_up,"Data from the assay component ATG_Oct_MLP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Oct_MLP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene POU2F1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is POU domain protein.",NP_002688.3, , , ,,,Active,1.0381856869312218,1.5319475088631245,10.616561674327128,1.0259838870236844,0.13553802345377633,1.0651169172521604,log2_fold_induction,2,0.6776901172688816,,1.1635078189090917,0.9300440507143383,0.5472672286766975,20,dna binding
ATG_PBREM_CIS_up,"Data from the assay component ATG_PBREM_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PBREM_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_001070948.1, , , ,"[8,107,58,8,107,58]","[456,715]",Active,1.5194536104435241,3.1693643349924456,38.31592213081883,1.5833792819743215,0.09588380822409588,1.2662113420767733,log2_fold_induction,2,0.4794190411204794,,1.3680743829663646,1.1790097863787505,0.9725162532748193,20,nuclear receptor
ATG_PXRE_CIS_up,"Data from the assay component ATG_PXRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PXRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1, , , ,"[8,11,60,8,11,60]",,Active,4.804374118435895,7.209390375771028,7.80206219049719,0.892209407765328,0.13328100901796647,4.0036451012721965,log2_fold_induction,1.47712125471966,0.6664050450898323,,0.4474906221411265,0.30788043071826254,0.3570979718419677,20,nuclear receptor
ATG_RORE_CIS_up,"Data from the assay component ATG_RORE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RORE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORA and RORB and RORC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.","NP_599023.1|NP_008845.2|NP_005051.2", , , ,,,Active,1.1912365746003168,1.7398569181645642,31.229775506458992,1.4945688623391802,0.13693500450105905,0.9926971455155159,log2_fold_induction,2,0.6846750225052953,,1.6040463128047049,1.2613954688468745,0.6962025494580822,20,nuclear receptor
ATG_Sp1_CIS_up,"Data from the assay component ATG_Sp1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Sp1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_612482.2, , , ,"[148,148]",,Active,0.5930407203639478,1.1287486897453363,29.30565608799558,1.4669514487071127,0.10507931938290839,0.593006714370053,log2_fold_induction,2,0.525396596914542,"[""Borderline active""]",1.578233624306592,1.4738141936987117,1.347671105177332,20,dna binding
ATG_SREBP_CIS_up,"Data from the assay component ATG_SREBP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_SREBP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SREBF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix leucine zipper.",NP_004167.3, , , ,"[62,61,58,34,34,62,61,58]",,Active,0.6964645022086396,1.916828314117339,17.292160940471813,1.2378492689176839,0.07266842805682862,0.5803870853511008,log2_fold_induction,2,0.3633421402841431,"[""Less than 50% efficacy""]",1.279019333157941,0.865167983230695,0.1961054437891896,20,dna binding
ATG_trAR_XSP2_dn,"The assay endpoint ATG_trAR_XSP2_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",, , , ,,,Active,2.0874882587221055,3.370522545559234,87.07359115040619,1.9398864563079448,0.2064455615319386,1.7395735489504043,log2_fold_induction,2.30102999566398,0.6193366845958158,"[""Hit-call potentially confounded by overfitting""]",1.7345572699094303,1.7345572699094303,1.4171789007327593,20,nuclear receptor
ATG_trAR_XSP2_dn,"The assay endpoint ATG_trAR_XSP2_dn was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",, , , ,,,Active,2.0874882587221055,3.370522545559234,87.07359115040619,1.9398864563079448,0.2064455615319386,1.7395735489504043,log2_fold_induction,2.30102999566398,0.6193366845958158,"[""Hit-call potentially confounded by overfitting""]",1.7345572699094303,1.7345572699094303,1.4171789007327593,20,nuclear receptor
ATG_trERa_XSP2_up,"The assay endpoint ATG_trERa_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",, , , ,,,Active,1.9032559990277607,2.1152526641936964,14.6144526699398,1.1647825551107662,0.29992571435167914,1.8478713558430986,log2_fold_induction,2.30102999566398,0.8997771430550374,,1.1233413963823597,1.1233413963823597,0.3300308943122897,20,nuclear receptor
ATG_VDRE_CIS_up,"Data from the assay component ATG_VDRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_VDRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene VDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_000367.1, , , ,,,Active,1.5880544247957382,2.186874405300426,9.514584255727673,0.9783898163342295,0.1452350826317871,1.492693182399295,log2_fold_induction,2,0.7261754131589355,,0.9313931659028918,0.7115927012458797,0.375656887050821,20,nuclear receptor
ATG_Xbp1_CIS_up,"Data from the assay component ATG_Xbp1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Xbp1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene XBP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_005071.2, , , ,,,Active,0.78515555493929,1.332999629713648,15.484914020476833,1.1899087982923449,0.11780281666064009,0.7708879808571835,log2_fold_induction,2,0.5890140833032005,,1.4194376662559276,1.1481166323788004,0.7312692072037523,20,dna binding
ATG_zfAR_XSP2_dn,ATG_zfAR_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,, , , ,,,Active,1.6086430211251608,1.9534528213712878,43.553340312536676,1.6390214687276394,0.2744956696720431,1.3595651614276871,log2_fold_induction,2.30102999566398,0.8234870090161293,"[""Hit-call potentially confounded by overfitting""]",1.6585667649083402,1.6585667649083402,0.7380437348864568,20,nuclear receptor
ATG_zfAR_XSP2_dn,ATG_zfAR_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,, , , ,,,Active,1.6086430211251608,1.9534528213712878,43.553340312536676,1.6390214687276394,0.2744956696720431,1.3595651614276871,log2_fold_induction,2.30102999566398,0.8234870090161293,"[""Hit-call potentially confounded by overfitting""]",1.6585667649083402,1.6585667649083402,0.7380437348864568,20,nuclear receptor
ATG_zfER2b_XSP2_up,"The assay endpoint ATG_zfER2b_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",, , , ,,,Active,0.65612747546162,1.2610962768478906,110.74019843324936,2.0443052973806104,0.17342780444477252,0.6503285513135384,log2_fold_induction,2.30102999566398,0.5202834133343175,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",2.117354042183802,2.117354042183802,1.9247814655826816,20,nuclear receptor
BSK_3C_HLADR_down,"Data from the assay component BSK_3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",NP_061984.2, , , ,,,Active,0.2795999997662808,3.5311391740174303,39.99999999999999,1.6020599913279623,0.025758990402599997,0.233,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.6020599913279623,1.6020599913279623,1.0090244468592227,20,cell adhesion molecules
BSK_3C_TissueFactor_down,"Data from the assay component BSK_3C_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_TissueFactor_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",NP_001984.1, , , ,,,Active,0.17039999997353805,1.3088498011798553,39.99999999999999,1.6020599913279623,0.04339688170481999,0.142,log10_fold_induction,1.60205999132796,0.13019064511446,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Less than 50% efficacy"",""Borderline active""]",1.6020599913279623,1.6020599913279623,-1.4794668793470143,20,cytokine
BSK_4H_Pselectin_down,"Data from the assay component BSK_4H_Pselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Pselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELP. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_002996.2, , , ,,,Active,0.18239999908650123,1.4878844127237632,39.99999999999999,1.6020599913279623,0.04086338910171,0.152,log10_fold_induction,1.60205999132796,0.12259016730513,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,1.219131933106629,20,cell adhesion molecules
BSK_4H_VEGFRII_down,"Data from the assay component BSK_4H_VEGFRII was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VEGFRII_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene KDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",NP_002244.1, , , ,"[43,43]",,Active,0.12184695994255697,1.1644023078702548,39.99999999999999,1.6020599913279623,0.03488111715312,0.107,log10_fold_induction,1.60205999132796,0.10464335145935999,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",1.6020599913279623,1.6020599913279623,1.3712201539865614,20,kinase
BSK_hDFCGF_Proliferation_down,"Data from the assay component BSK_hDFCGF_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_hDFCGF_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.17879999999757668,1.3195223197017525,40.000000000000014,1.6020599913279625,0.0451678604517,0.149,log10_fold_induction,1.60205999132796,0.1355035813551,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",1.6020599913279625,1.6020599913279625,0.8895403608724808,20,cell cycle
BSK_LPS_CD40_down,"Data from the assay component BSK_LPS_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001241.1, , , ,,,Active,0.19799994768491896,1.4344843868529564,40.000000000000014,1.6020599913279625,0.0460095510042,0.165,log10_fold_induction,1.60205999132796,0.13802865301259998,"[""Borderline active"",""Less than 50% efficacy"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.6020599913279625,1.6020599913279625,1.3951958097408907,20,cytokine
BSK_LPS_MCP1_down,"Data from the assay component BSK_LPS_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1, , , ,,,Active,0.13439999996331084,1.4987767546360735,40.000000000000014,1.6020599913279625,0.029891042711459998,0.112,log10_fold_induction,1.60205999132796,0.08967312813438,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,0.6963281642275334,20,cytokine
BSK_LPS_PGE2_up,"Data from the assay component BSK_LPS_PGE2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_PGE2_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PTGER2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_000947.2, , , ,,,Active,0.14700500943145067,1.042814880730095,40.000000000000014,1.6020599913279625,0.04698980683529999,0.147,log10_fold_induction,1.60205999132796,0.14096942050589997,"[""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,0.9024355477215814,20,gpcr
BSK_LPS_TissueFactor_down,"Data from the assay component BSK_LPS_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TissueFactor_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",NP_001984.1, , , ,,,Active,0.2063999999993369,1.7028984727457013,40.000000000000014,1.6020599913279625,0.0404017039776,0.172,log10_fold_induction,1.60205999132796,0.1212051119328,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,0.4890304590850747,20,cytokine
BSK_LPS_TNFa_up,"Data from the assay component BSK_LPS_TNFa was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TNFa_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene TNF. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_000585.2, , , ,,,Active,0.19799999999475532,1.4541535607712595,40.000000000000014,1.6020599913279625,0.04538722854225,0.165,log10_fold_induction,1.60205999132796,0.13616168562675,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,-0.4894174121266559,20,cytokine
BSK_LPS_VCAM1_down,"Data from the assay component BSK_LPS_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1, , , ,,,Active,0.1499999999426554,1.894387969752781,40.000000000000014,1.6020599913279625,0.0224178208338,0.125,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,1.0003531096143186,20,cell adhesion molecules
BSK_SAg_CD38_down,"Data from the assay component BSK_SAg_CD38 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD38_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD38. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""other cytokine"".",NP_001766.2, , , ,,,Active,0.1331999999597032,1.682216517274658,40.000000000000014,1.6020599913279625,0.0243080164845,0.111,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.6020599913279625,1.6020599913279625,0.9370506615512213,20,cytokine
BSK_SAg_CD40_down,"Data from the assay component BSK_SAg_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001241.1, , , ,,,Active,0.18239999999225764,1.8295152964265182,40.000000000000014,1.6020599913279625,0.0332328459435,0.152,log10_fold_induction,1.60205999132796,0.09969853783049999,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,0.7038032276197027,20,cytokine
BSK_SAg_CD69_down,"Data from the assay component BSK_SAg_CD69 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD69_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD69. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001772.1, , , ,,,Active,0.19919999997480814,1.8813918138764054,40.000000000000014,1.6020599913279625,0.03529302057225,0.166,log10_fold_induction,1.60205999132796,0.10587906171674999,"[""Borderline active"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,0.8780787924927929,20,cytokine
BSK_SAg_Eselectin_down,"Data from the assay component BSK_SAg_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_000441.2, , , ,,,Active,0.17661113436147127,1.5390081499323727,40.000000000000014,1.6020599913279625,0.038252154885,0.162,log10_fold_induction,1.60205999132796,0.114756464655,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,0.21079305029377637,20,cell adhesion molecules
BSK_SAg_Proliferation_down,"Data from the assay component BSK_SAg_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_SAg_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.2531999999424601,2.1156461293825255,40.000000000000014,1.6020599913279625,0.0398932500141,0.211,log10_fold_induction,1.60205999132796,0.1196797500423,"[""Less than 50% efficacy"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",1.6020599913279625,1.6020599913279625,1.035797996635727,20,cell cycle
CCTE_Deisenroth_AIME_384WELL_CTox_Active_dn,"CCTE_Deisenroth_AIME_384WELL_CTox_Active_dn is a component of the CCTE_Deisenroth_AIME_384WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/beta-naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates cytotoxicity in metabolism positive mode. Using a type of flourescent probe in VM7Luc cells, loss-of-signal activity can be used to understand loss of viability. This assay endpoint, CCTE_Deisenroth_AIME_384WELL_CTox_Active_dn, was analyzed in the positive fitting direction in the ERTA assay. ",, , , ,,,Active,0.5310561710667536,1.2616963160348829,64.48892450951804,1.809485134210153,0.14030216418894872,0.4634242113086993,log2_fold_induction,2,0.4209064925668462,"[""Borderline active"",""Only one conc above baseline, active""]",2.195906755404594,2.195906755404594,1.1761316076417194,99.98370361328125,protease
CCTE_Deisenroth_AIME_384WELL_CTox_Inactive_dn,"CCTE_Deisenroth_AIME_384WELL_CTox_Inactive_dn is a component of the CCTE_Deisenroth_AIME_384WELL assay that measures the effect of retroftting the VM7Luc ERTA assay with the Alginate Immobolization of Metabolic Enzymes (AIME) metabolism method. AIME is optimized to impart phase I hepatic metabolism using phenobarbital/beta-naphthoflavone induced hepatic S9 from male Sprague Dawley rats. Parent chemicals are incubated for 2 hours in the AIME assay prior to transfer to the VM7Luc ERTA assay plate. The AIME metabolism assay is run simultaneously in negative (inactive) and positive (active) modes to evaluate the activity of parent and metabolites, respectively. This endpoint evaluates cytotoxicity in metabolism negative mode. Using a type of flourescent probe in VM7Luc cells, loss-of-signal activity can be used to understand loss of viability. This assay endpoint, CCTE_Deisenroth_AIME_384WELL_CTox_Inactive_dn, was analyzed in the positive fitting direction in the ERTA assay. ",, , , ,,,Active,0.875805292356267,2.392983053073637,116.01005208071766,2.06449562176181,0.121996307945899,0.706421232305958,log2_fold_induction,2.30102999566398,0.365988923837697,,1.99466096551648,1.99466096551648,1.60154927384554,99.98370361328125,protease
CCTE_GLTED_hDIO1_dn,"Data from the assay component CCTE_GLTED_hDIO1 was analyzed into 1 assay endpoint. This assay endpoint, CCTE_GLTED_hDIO1_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DIO1. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 1'.",, , , ,,,Active,76.88518053690393,3.8442590268451964,53.44710291547065,1.7279241693778382,5.074688733372146,64.3695920889987,percent_activity,2.30102999566398,20,,1.3819209321716042,1.2649184941415101,1.0006258476281293,20,deiodinase
CCTE_GLTED_hDIO1_dn,"Data from the assay component CCTE_GLTED_hDIO1 was analyzed into 1 assay endpoint. This assay endpoint, CCTE_GLTED_hDIO1_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DIO1. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 1'.",, , , ,,,Active,76.88518053690393,3.8442590268451964,53.44710291547065,1.7279241693778382,5.074688733372146,64.3695920889987,percent_activity,2.30102999566398,20,,1.3819209321716042,1.2649184941415101,1.0006258476281293,20,deiodinase
CCTE_Mundy_HCI_CDI_NOG_BPCount_loss,"Data from the assay component CCTE_Mundy_HCI_CDI_NOG_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_CDI_NOG_BPCount_loss in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects.",, , , ,,,Active,100.10687150351656,2.255496450235375,12.767304550874128,1.106099218152675,14.794506621527423,100,percent_activity,1.47712125471966,44.38351986458227,"[""Only one conc above baseline, active""]",1.0937430363133747,1.0937430363133747,0.9867779045754229,20.00040054321289,neurodevelopment
CCTE_Mundy_HCI_CDI_NOG_NeuriteCount_loss,"Data from the assay component CCTE_Mundy_HCI_CDI_NOG_NeuriteCount was analyzed at the endpoint CCTE_Mundy_HCI_CDI_NOG_NeuriteCount_loss in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects.",, , , ,,,Active,100.64781977654573,3.3549273258848578,15.953731290156757,1.2028622729236265,3.8676521739130183,100,percent_activity,1.47712125471966,30,"[""Only one conc above baseline, active""]",1.1562475342658667,1.0919525622290283,1.0832804054730547,20.00040054321289,neurodevelopment
CCTE_Mundy_HCI_CDI_NOG_NeuriteLength_loss,"Data from the assay component CCTE_Mundy_HCI_CDI_NOG_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_CDI_NOG_NeuriteLength_loss in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects.",, , , ,,,Active,100.17783666119458,3.339261222039819,13.579393764687861,1.1328803818349307,9.137503488840819,100,percent_activity,1.47712125471966,30,"[""Only one conc above baseline, active""]",1.086742208955031,1.0798795946911168,1.0135914515985975,20.00040054321289,neurodevelopment
CCTE_Mundy_HCI_CDI_NOG_NeuronCount_loss,"Data from the assay component CCTE_Mundy_HCI_CDI_NOG_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_CDI_NOG_NeuronCount_loss in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand developmental effects.",, , , ,,,Active,99.43601806076266,3.3145339353587553,24.845710765700773,1.3952514251993409,8.041265384435855,81.41935483870968,percent_activity,1.47712125471966,30,"[""Only one conc above baseline, active""]",1.3496934804946812,1.3334489480420784,1.2759711099126756,20.00040054321289,neurodevelopment
CCTE_Mundy_HCI_Cortical_NOG_BPCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_NOG_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_BPCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,40.694149757235046,1.3564716585745016,25.835837483716134,1.412222544018376,7.341623108665738,30.127298444130123,percent_activity,1.47712125471966,30,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Borderline active""]",1.46821944353763,1.421195768224116,1.2929421762989455,20.00040054321289,neurodevelopment
CCTE_Mundy_HCI_Cortical_NOG_BPCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_NOG_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_BPCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,40.694149757235046,1.3564716585745016,25.835837483716134,1.412222544018376,7.341623108665738,30.127298444130123,percent_activity,1.47712125471966,30,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Borderline active""]",1.46821944353763,1.421195768224116,1.2929421762989455,20.00040054321289,neurodevelopment
CCTE_Padilla_ZF_144hpf_TERATOSCORE_up,"Data from the assay component CCTE_Padilla_ZF_144hpf_TERATOSCORE was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Padilla_ZF_144hpf_TERATOSCORE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defect  as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""malformation"" intended target family, where the subfamily is ""total"".",, , , ,,,Active,119.646796514448,5.9823398257224,14.072917133555075,1.14838413039078,1.53481347591287,99.1770149299192,percent_activity,1.90308998699194,20,"[""Noisy data"",""Noisy data""]",0.308867001149292,-0.534037668928912,-0.000260305724066878,20,malformation
CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean_up,"Data from the assay component CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,51.94792911173505,1.3219014255577428,12.0053204453841,1.0793737567133062,13.099294724848574,55.39058081477797,percent_activity,1.47712125471966,39.29788417454572,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Borderline active""]",1.1409255090876467,1.1409255090876467,0.9600602671269658,20.00040054321289,neuroactivity
CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean_up,"Data from the assay component CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,75.86503741056485,3.6771264897082974,26.650734635280216,1.4257091849817671,6.877203129753559,52.43025473361035,percent_activity,1.47712125471966,20.631609389260674,"[""Only one conc above baseline, active""]",1.3722505493397035,1.3722505493397035,1.3064288172540612,20.00040054321289,neuroactivity
CCTE_Shafer_MEA_dev_AB_dn,"Data from the assay component CCTE_Shafer_MEA_dev_AB was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_AB_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand cell viability.",, , , ,,,Active,118.401919821971,6.07015499477585,24.871452743345994,1.39570115318278,6.50186142549743,97.7758679958749,percent_activity,1.47712125471966,19.5055842764923,"[""Noisy data"",""Only highest conc above baseline, active""]",1.30746149538519,1.30746149538519,1.2762692436209,20.00040054321289,cell cycle
CCTE_Shafer_MEA_dev_AB_dn,"Data from the assay component CCTE_Shafer_MEA_dev_AB was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_AB_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand cell viability.",, , , ,,,Active,118.401919821971,6.07015499477585,24.871452743345994,1.39570115318278,6.50186142549743,97.7758679958749,percent_activity,1.47712125471966,19.5055842764923,"[""Noisy data"",""Only highest conc above baseline, active""]",1.30746149538519,1.30746149538519,1.2762692436209,20.00040054321289,cell cycle
CCTE_Shafer_MEA_dev_active_electrodes_number_dn,"Data from the assay component CCTE_Shafer_MEA_dev_active_electrodes_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_active_electrodes_number_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.213876156394,3.7852266725738994,13.903335016236024,1.14311898769452,8.825,100,percent_activity,1.47712125471966,26.475,"[""Noisy data""]",1.08748773139102,1.08748773139102,1.02378786212548,20.00040054321289,neurodevelopment
CCTE_Shafer_MEA_dev_active_electrodes_number_dn,"Data from the assay component CCTE_Shafer_MEA_dev_active_electrodes_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_active_electrodes_number_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.213876156394,3.7852266725738994,13.903335016236024,1.14311898769452,8.825,100,percent_activity,1.47712125471966,26.475,"[""Noisy data""]",1.08748773139102,1.08748773139102,1.02378786212548,20.00040054321289,neurodevelopment
CCTE_Shafer_MEA_dev_correlation_coefficient_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_correlation_coefficient_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_correlation_coefficient_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999999529036,2.353051166199572,9.480248165507236,0.976819706061667,16.9992052946372,100,percent_activity,1.47712125471966,50.9976158839116,"[""Only highest conc above baseline, active"",""Noisy data""]",0.829726904582459,0.829726904582459,-0.0920836013750992,20.00040054321289,neurodevelopment
CCTE_Shafer_MEA_dev_correlation_coefficient_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_correlation_coefficient_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_correlation_coefficient_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999999529036,2.353051166199572,9.480248165507236,0.976819706061667,16.9992052946372,100,percent_activity,1.47712125471966,50.9976158839116,"[""Only highest conc above baseline, active"",""Noisy data""]",0.829726904582459,0.829726904582459,-0.0920836013750992,20.00040054321289,neurodevelopment
CCTE_Shafer_MEA_dev_firing_rate_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_firing_rate_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_firing_rate_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999651267554,1.6978238432312744,24.57840273029476,1.39055365609483,23.5595017205814,100,percent_activity,-1,70.6785051617442,"[""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Noisy data""]",1.41008543109285,1.41008543109285,1.27127333912094,20.00040054321289,neurodevelopment
CCTE_Shafer_MEA_dev_firing_rate_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_firing_rate_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_firing_rate_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999651267554,1.6978238432312744,24.57840273029476,1.39055365609483,23.5595017205814,100,percent_activity,-1,70.6785051617442,"[""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Noisy data""]",1.41008543109285,1.41008543109285,1.27127333912094,20.00040054321289,neurodevelopment
CCTE_Shafer_MEA_dev_interburst_interval_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_interburst_interval_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_interburst_interval_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.998759491055,1.8561874451466256,24.54940882102603,1.39004103825705,21.5493249895668,100,percent_activity,1.47712125471966,64.6479749687004,"[""Only highest conc above baseline, active"",""Borderline active""]",1.39846993281112,1.39846993281112,1.27076070401352,20.00040054321289,neurodevelopment
CCTE_Shafer_MEA_dev_interburst_interval_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_interburst_interval_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_interburst_interval_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.998759491055,1.8561874451466256,24.54940882102603,1.39004103825705,21.5493249895668,100,percent_activity,1.47712125471966,64.6479749687004,"[""Only highest conc above baseline, active"",""Borderline active""]",1.39846993281112,1.39846993281112,1.27076070401352,20.00040054321289,neurodevelopment
CCTE_Shafer_MEA_dev_LDH_dn,"Data from the CCTE_Shafer_MEA_dev_LDH was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_LDH_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand cell viability.",, , , ,,,Active,99.3992519965116,4.159860882126923,16.51059495479551,1.21776272322822,7.96495001580351,99.1013841582723,percent activity,1.47712125471966,23.8948500474105,,1.14925040135261,1.14925040135261,1.08692109467544,20.00040054321289,cell cycle
CCTE_Shafer_MEA_dev_LDH_dn,"Data from the CCTE_Shafer_MEA_dev_LDH was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_LDH_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand cell viability.",, , , ,,,Active,99.3992519965116,4.159860882126923,16.51059495479551,1.21776272322822,7.96495001580351,99.1013841582723,percent activity,1.47712125471966,23.8948500474105,,1.14925040135261,1.14925040135261,1.08692109467544,20.00040054321289,cell cycle
CCTE_Shafer_MEA_dev_network_spike_peak_dn,"Data from the CCTE_Shafer_MEA_dev_network_spike_peak was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_network_spike_peak_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999770819285,4.427134749921208,18.13349780566105,1.25848158408332,9.03517192629845,100,percent activity,1.47712125471966,27.1055157788953,"[""Noisy data""]",1.09059239137602,1.09059239137602,0.958990714285062,20.00040054321289,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_peak_dn,"Data from the CCTE_Shafer_MEA_dev_network_spike_peak was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_network_spike_peak_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999770819285,4.427134749921208,18.13349780566105,1.25848158408332,9.03517192629845,100,percent activity,1.47712125471966,27.1055157788953,"[""Noisy data""]",1.09059239137602,1.09059239137602,0.958990714285062,20.00040054321289,neurodevelopment
CCTE_Shafer_MEA_dev_per_burst_spike_percent_dn,"Data from the CCTE_Shafer_MEA_dev_per_burst_spike_percent was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_burst_spike_percent_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.094446427853,2.951150421747518,12.475736154193445,1.09606618141137,11.305698018671,100,percent activity,-1,33.917094056013,"[""Noisy data"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Borderline active""]",1.05975693775383,1.05975693775383,0.97671059212925,20.00040054321289,neurodevelopment
CCTE_Shafer_MEA_dev_per_burst_spike_percent_dn,"Data from the CCTE_Shafer_MEA_dev_per_burst_spike_percent was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_burst_spike_percent_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.094446427853,2.951150421747518,12.475736154193445,1.09606618141137,11.305698018671,100,percent activity,-1,33.917094056013,"[""Noisy data"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Borderline active""]",1.05975693775383,1.05975693775383,0.97671059212925,20.00040054321289,neurodevelopment
CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_dn,"Data from the CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999241963581,2.2002776779536397,24.54428136228679,1.38995032081306,18.1794087728033,100,percent activity,1.47712125471966,54.5382263184099,"[""Only highest conc above baseline, active""]",1.3800401042074,1.3800401042074,1.27067000198685,20.00040054321289,neurodevelopment
CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_dn,"Data from the CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999241963581,2.2002776779536397,24.54428136228679,1.38995032081306,18.1794087728033,100,percent activity,1.47712125471966,54.5382263184099,"[""Only highest conc above baseline, active""]",1.3800401042074,1.3800401042074,1.27067000198685,20.00040054321289,neurodevelopment
CCTE_Shafer_MEA_dev_per_network_spike_spike_percent_dn,"Data from the CCTE_Shafer_MEA_dev_per_network_spike_spike_percent was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_network_spike_spike_percent_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999999896189,2.1561850183826756,5.556983697058829,0.744839122664851,18.5512836905804,100,percent activity,1.47712125471966,55.6538510717412,,0.631836361627699,0.631836361627699,-0.966038131830633,20.00040054321289,neurodevelopment
CCTE_Shafer_MEA_dev_per_network_spike_spike_percent_dn,"Data from the CCTE_Shafer_MEA_dev_per_network_spike_spike_percent was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_network_spike_spike_percent_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999999896189,2.1561850183826756,5.556983697058829,0.744839122664851,18.5512836905804,100,percent activity,1.47712125471966,55.6538510717412,,0.631836361627699,0.631836361627699,-0.966038131830633,20.00040054321289,neurodevelopment
CCTE_Shafer_MEA_dev_spike_duration_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_spike_duration_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_spike_duration_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.984136586709,2.8214700567879754,24.53358423420688,1.38976100109777,14.1751326048452,100,percent_activity,1.47712125471966,42.5253978145356,"[""Noisy data""]",1.35720820769273,1.35720820769273,1.2704805449777,20.00040054321289,neurodevelopment
CCTE_Shafer_MEA_dev_spike_duration_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_spike_duration_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_spike_duration_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.984136586709,2.8214700567879754,24.53358423420688,1.38976100109777,14.1751326048452,100,percent_activity,1.47712125471966,42.5253978145356,"[""Noisy data""]",1.35720820769273,1.35720820769273,1.2704805449777,20.00040054321289,neurodevelopment
CCTE_Simmons_AUR_TPO_dn,"Data from the assay component CCTE_Simmons_AUR_TPO was analyzed at the endpoint, CCTE_Simmons_AUR_TPO_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, the Amplex UltraRed assay, loss-of-signal activity can be used to understand decreased peroxidase activity in the presence of excess hydrogen peroxidase. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is peroxidase.",P14650.1, , , ,,,Active,125.507510764552,6.2753755382276,8.391870919524397,0.923858795089051,5.55295187687267,101.710141537022,percent_activity,1.95424250943932,20,,0.209434801365116,0.117517602046447,-0.0200395130708672,20,oxidoreductase
CCTE_Simmons_CellTiterGLO_HEK293T,"Data from the assay component CCTE_Simmons_CellTiterGLO_HEK293T was analyzed at the endpoint, CCTE_Simmons_CellTiterGLO_HEK293T_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, measures of ATP content for loss-of-signal activity can be used to understand the viability. This assay was run in parallel with aeid 1508 as a means of indicating the range of chemical cytotoxicity or reactivity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,48.4540399949393,2.422701999746965,61.25693214482307,1.78715524278173,5.60777764752233,39.3022883107869,percent_activity,2,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.71891171739519,1.66494455354004,1.36184535860927,20,cell cycle
CCTE_Simmons_GUA_TPO_dn,"Data from the assay component CCTE_Simmons_GUA_TPO was analyzed at the endpoint, CCTE_Simmons_GUA_TPO_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, measures of enzyme activity for loss-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene TPO. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is peroxidase.",, , , ,,,Active,69.5298602248431,3.4764930112421553,60.69579731412183,1.78315862078737,3.7084553570984,55.862977602108,percent_activity,2.69897000433602,20,,0.532511274595574,-0.503652614940486,-1.24708114503602,100,oxidoreductase
CEETOX_H295R_OHPROG_up,"Data from the assay component CEETOX_H295R_OHPROG_up was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_OHPROG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of 17alpha-hydroxyprogesterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.",NP_000917.3, , , ,,,Active,1.59795283070718,1.766332783349926,2.1765560376719493,0.337769852995101,0.150778762810161,1.40772941889119,log2_fold_induction,1,0.904672576860966,,0.426707659897527,0.0272271758314984,-0.396494989760539,100,steroid hormone
CLD_CYP1A1_24hr,"Data from the assay component CLD_CYP1A1_24hr was analyzed at the endpoint, CLD_CYP1A1_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP1A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",NP_000490.1, , , ,,,Active,4.7080513924918,4.7080513924918,3.8878477668449487,0.589709251286755,0.653028314193223,4.63893427308842,log2_fold_induction,1.60205999132796,1,,0.502637038409659,0.567202308495005,0.443722027994629,20,cyp
CLD_CYP1A1_48hr,"Data from the assay component CLD_CYP1A1_48hr was analyzed at the endpoint, CLD_CYP1A1_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP1A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",NP_000490.1, , , ,,,Active,2.17412027340128,2.17412027340128,1.1159698575117878,0.0476524644106184,0.615334596430808,2.09129570663923,log2_fold_induction,1.60205999132796,1,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",-0.0178250477432953,0.752281698612254,-0.848619330561951,20,cyp
CLD_CYP1A1_6hr,"Data from the assay component CLD_CYP1A1_6hr was analyzed at the endpoint, CLD_CYP1A1_6hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP1A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",NP_000490.1, , , ,,,Active,2.2493143533334,2.2493143533334,4.414147987319015,0.644846889088137,0.591699663490599,2.24373124472116,log2_fold_induction,1.60205999132796,1,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",0.631065323613903,0.726569234507243,0.508809645556976,20,cyp
CLD_CYP1A2_24hr,"Data from the assay component CLD_CYP1A2_24hr was analyzed at the endpoint, CLD_CYP1A2_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP1A2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",NP_000752.2, , , ,,,Active,3.74872655539752,3.74872655539752,4.58608008260785,0.661441634155591,0.473054592292178,2.65517006030607,log2_fold_induction,1.60205999132796,1,,-0.456988169349612,0.113239248038995,-1.76893097530398,20,cyp
CLD_CYP1A2_48hr,"Data from the assay component CLD_CYP1A2_48hr was analyzed at the endpoint, CLD_CYP1A2_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP1A2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",NP_000752.2, , , ,,,Active,2.46571911360065,2.46571911360065,0.661122101136086,-0.179718324247282,0.353101746564916,2.13315904036284,log2_fold_induction,0.602059991327962,1,,-0.343398110363275,-0.30105276926441,-1.12033562739402,20,cyp
CLD_CYP1A2_6hr,"Data from the assay component CLD_CYP1A2_6hr was analyzed at the endpoint, CLD_CYP1A2_6hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP1A2. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",NP_000752.2, , , ,,,Active,2.27467661072714,2.27467661072714,15.40970780898035,1.18779440392604,0.440691670003288,1.48527939499122,log2_fold_induction,1.60205999132796,1,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.03222655089563,1.39789183941816,-0.220644254645924,20,cyp
CLD_CYP2B6_24hr,"Data from the assay component CLD_CYP2B6_24hr was analyzed at the endpoint, CLD_CYP2B6_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2B6. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",NP_000758.1, , , ,,,Active,4.65723047323559,4.65723047323559,7.321622658795475,0.864607342487906,0.415288000995156,3.81468445467425,log2_fold_induction,1.60205999132796,1,,0.210383447777192,0.356405049017329,-0.243952842732776,20,cyp
CLD_CYP2B6_48hr,"Data from the assay component CLD_CYP2B6_48hr was analyzed at the endpoint, CLD_CYP2B6_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2B6. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",NP_000758.1, , , ,,,Active,4.74932611748977,4.74932611748977,7.818149536542105,0.893103972859339,0.450385337247368,3.75575206689253,log2_fold_induction,1.60205999132796,1,,0.140387462531784,0.367812409285594,-0.358346616280191,20,cyp
CLD_CYP2B6_6hr,"Data from the assay component CLD_CYP2B6_6hr was analyzed at the endpoint, CLD_CYP2B6_6hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2B6. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",NP_000758.1, , , ,,,Active,2.62983223502075,2.62983223502075,0.4526408545950641,-0.344246249929568,0.396566308888419,2.71245226436909,log2_fold_induction,0.602059991327962,1,,-0.37137361117137,-0.35485531795747,-0.466268155398704,20,cyp
CLD_CYP3A4_24hr,"Data from the assay component CLD_CYP3A4_24hr was analyzed at the endpoint, CLD_CYP3A4_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP3A4. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",NP_059488.2, , , ,,,Active,4.58930725091723,4.58930725091723,5.440924597534652,0.73567270732448,0.719693813962598,4.55812198945337,log2_fold_induction,1.60205999132796,1,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",0.654938209898461,0.728199075670831,0.596864035227866,20,cyp
CLD_CYP3A4_48hr,"Data from the assay component CLD_CYP3A4_48hr was analyzed at the endpoint, CLD_CYP3A4_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP3A4. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",NP_059488.2, , , ,,,Active,3.59920329580515,3.59920329580515,4.828473238211288,0.683809828672977,0.783724870256564,3.56571600845336,log2_fold_induction,1.60205999132796,1,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",0.618849807530787,0.726881647236837,0.534384565011585,20,cyp
CLD_CYP3A4_6hr,"Data from the assay component CLD_CYP3A4_6hr was analyzed at the endpoint, CLD_CYP3A4_6hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP3A4. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",NP_059488.2, , , ,,,Active,3.38640025562419,3.38640025562419,1.1695719160222768,0.0680269313793557,0.56118133263598,2.63214948493872,log2_fold_induction,0.602059991327962,1,,-0.333178571176514,0.0627657418376851,-0.945485045835789,20,cyp
CLD_UGT1A1_24hr,"Data from the assay component CLD_UGT1A1_24hr was analyzed at the endpoint, CLD_UGT1A1_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene UGT1A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is glucuronosyltransferase.",NP_000454.1, , , ,,,Active,2.03566054000759,2.03566054000759,12.580657891852846,1.09970335266176,0.20905374360745,1.51174569527617,log2_fold_induction,1.60205999132796,1,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.08244805441926,0.701270590127655,0.0176717770145813,20,transferase
CLD_UGT1A1_48hr,"Data from the assay component CLD_UGT1A1_48hr was analyzed at the endpoint, CLD_UGT1A1_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene UGT1A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is glucuronosyltransferase.",NP_000454.1, , , ,,,Active,1.6385371062306,1.6385371062306,6.212231901106361,0.793247659466536,0.187852051437315,1.31447335265234,log2_fold_induction,1.60205999132796,1,,1.10259778390544,0.347892073419608,-0.722019471271416,20,transferase
CLD_UGT1A1_6hr,"Data from the assay component CLD_UGT1A1_6hr was analyzed at the endpoint, CLD_UGT1A1_6hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene UGT1A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is glucuronosyltransferase.",NP_000454.1, , , ,,,Active,1.30940523117792,1.30940523117792,1.7285098059339543,0.237671847662589,0.203421751283061,1.25146070210643,log2_fold_induction,1.60205999132796,1,,0.778022445400122,0.175047708586593,-0.774405672382322,20,transferase
IUF_NPC2a_ radial_glia_migration_120hr_dn,"Data from the IUF_NPC2a_radial_glia_migration_120hr component was analyzed at the endpoint IUF_NPC2a_ radial_glia_migration_120hr_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of migration reporter, loss-of-signal activity can be used to understand developmental effects.",, , , ,,,Active,23.022862894592315,2.1008092824248736,8.381445433685927,0.9233189219407094,5.479522364833141,23.80758898187106,percent_activity,1.30102999566398,10.959044729666282,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",0.9181048503252321,0.9729888334341047,0.8040372073728486,20.00040054321289,neurodevelopment
IUF_NPC2a_radial_glia_migration_72hr_dn,"Data from the IUF_NPC2a_radial_glia_migration_72hr component was analyzed at the endpoint IUF_NPC2a_radial_glia_migration_72hr_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of migration reporter, loss-of-signal activity can be used to understand developmental effects.",, , , ,,,Active,20.033172265046183,1.893114875156908,8.61623854893091,0.9353177143208218,5.291060919741007,20.007217618375737,percent_activity,1.30102999566398,10.582121839482014,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",0.9415138753435046,1.0087199528517998,0.8148793806281015,20.00040054321289,neurodevelopment
IUF_NPC5_oligodendrocyte_differentiation_120hr_dn,"Data from the IUF_NPC5_oligodendrocyte_differentiation_120hr component was analyzed at the endpoint IUF_NPC5_oligodendrocyte_differentiation_120hr_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of differentiation reporter, loss-of-signal activity can be used to understand developmental effects.",, , , ,,,Active,66.297869211652,1.4063850342001032,3.8566927622554297,0.5862150428142461,23.570312396476698,64.10342591420977,percent_activity,1.30102999566398,47.140624792953396,,1.8897560221289231,,-2.5945933199774123,20.00040054321289,neurodevelopment
LTEA_HepaRG_ABCG2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_004818.2, , , ,,,Active,1.02703453286226,1.704239058104852,21.675840514184436,1.33597594691387,0.200878417062049,0.845755718556531,log2_fold_induction,2,0.602635251186147,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.58670497109634,1.58670497109634,-0.235185485333237,20,transporter
LTEA_HepaRG_CDKN1A_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000380.1, , , ,,,Active,0.640244027741902,1.6443302014377084,2.154983325878547,0.333443914168698,0.129788211471984,0.415219588373715,log2_fold_induction,0.477121254719662,0.389364634415952,"[""Only one conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Only one conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",0.506961019239847,0.506961019239847,-0.533946135461945,20,cell cycle
LTEA_HepaRG_CYP1A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000490.1, , , ,"[57,57]",,Active,4.9117941261353,5.454030003731698,34.20334911311111,1.53406863325293,0.300193564683644,4.504149540573,log2_fold_induction,2,0.900580694050932,,1.24402844468422,1.24402844468422,1.10745231178991,20,cyp
LTEA_HepaRG_CYP1A2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000752.2, , , ,"[131,131]",,Active,3.72610825808829,3.924314330540588,38.65549814829681,1.58721127433825,0.316497604782422,3.02799383138407,log2_fold_induction,2,0.949492814347266,,1.25239578232964,1.25239578232964,0.901634696111997,20,cyp
LTEA_HepaRG_CYP2B6_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000758.1, , , ,,,Active,2.99407579758705,3.9716808836616995,6.545889835045601,0.8159686920147,0.251285361310856,2.77053842652048,log2_fold_induction,2,0.753856083932568,,0.345790327742162,0.345790327742162,-0.132577023333926,20,cyp
LTEA_HepaRG_CYP2C19_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000760.1, , , ,,,Active,0.945330374455183,1.6856468989159936,38.71000235228993,1.58782319770972,0.186937207917646,0.764365174247225,log2_fold_induction,2,0.560811623752938,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.69910028209432,1.69910028209432,0.939954627793861,20,cyp
LTEA_HepaRG_CYP3A4_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_059488.2, , , ,,,Active,2.09996149875643,1.7697583358992333,28.776860634867656,1.45904341352969,0.395526977922934,1.77321834806809,log2_fold_induction,2,1.1865809337688,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.54436056343709,1.54436056343709,0.742665025686366,20,cyp
LTEA_HepaRG_IGFBP1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000587.1, , , ,,,Active,1.17291181045766,1.354542765122034,41.85201988146343,1.62171642295544,0.288636589078576,0.93354191745626,log2_fold_induction,2,0.865909767235728,"[""Only highest conc above baseline, active"",""Borderline active"",""Borderline active"",""Only highest conc above baseline, active""]",1.98743675303908,1.98743675303908,0.846762895759891,20,transporter
LTEA_HepaRG_NQO1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000894.1, , , ,,,Active,1.16270856101633,1.4783350062236953,55.339542732382796,1.74303556626819,0.262166233436355,0.871558188364924,log2_fold_induction,2,0.786498700309065,"[""Borderline active"",""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active""]",1.92334861922175,1.92334861922175,1.20579029387597,20,oxidoreductase
LTEA_HepaRG_UGT1A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000454.1, , , ,,,Active,1.69034349161314,2.5520920588703637,37.20060724247683,1.57055002912664,0.220778803248623,1.44022856643684,log2_fold_induction,2,0.662336409745869,,1.4624030696006,1.4624030696006,1.03001058912262,20,transferase
NVS_ADME_hCYP1A1,"Data from the assay component NVS_ADME_hCYP1A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP1A1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000490.1, , , ,"[57,57]",,Active,98.0225536082357,4.9011276804117845,0.330899488616153,-0.480303904013778,1.8911470059282,96.9090238051301,percent_activity,1.30102999566398,20,,-1.01692309765209,-1.58005224067062,-1.34646318168973,20,cyp
NVS_ADME_hCYP1A2,"Data from the assay component NVS_ADME_hCYP1A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP1A2, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1A2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000752.2, , , ,"[131,131]",,Active,88.8544279611399,4.442721398056995,2.6799813138201474,0.428131765919427,1.22140528143636,74.0453566451286,percent_activity,1.30102999566398,20,,-0.292292709191995,-1.40533962638191,-0.852287778194645,20,cyp
NVS_ADME_hCYP1B1,"Data from the assay component NVS_ADME_hCYP1B1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP1B1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1B1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000095.2, , , ,,,Active,41.8804576483242,1.6508766129445767,0.4244019985772626,-0.372222579603324,4.22810294845157,45.4727781723979,percent_activity,0.845098040014257,25.3686176907094,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",-0.149803458173043,-0.804009259521456,-1.51024007830007,20,cyp
NVS_ADME_hCYP2B6,"Data from the assay component NVS_ADME_hCYP2B6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2B6, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2B6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000758.1, , , ,,,Active,91.6702654902501,4.583513274512505,0.2827557019971579,-0.548588628415124,1.55763530034319,91.7429669995298,percent_activity,1.30102999566398,20,,-0.986081190012129,-1.55088177990982,-1.30173170673506,20,cyp
NVS_ADME_hCYP2C18,"Data from the assay component NVS_ADME_hCYP2C18 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C18, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C18. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000763.1, , , ,,,Active,98.4602728443566,4.92301364221783,1.7221449854554964,0.236069711422322,2.2402555060755,88.8168857618959,percent_activity,1.30102999566398,20,,-0.440553245598723,-1.057788966155,-0.851600154805049,20,cyp
NVS_ADME_hCYP2C19,"Data from the assay component NVS_ADME_hCYP2C19 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C19, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C19. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000760.1, , , ,,,Active,103.797678351385,5.18988391756925,0.21121164201325587,-0.675282147109971,2.60299124232151,106.255486963671,percent_activity,1.30102999566398,20,,-0.960600109621234,-1.17494290532226,-1.11286115288001,20,cyp
NVS_ADME_hCYP2C8,"Data from the assay component NVS_ADME_hCYP2C8 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C8, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000761.3, , , ,,,Active,33.0839050410369,1.1436603391166422,7.0873830598298895,0.850485906202258,4.82134772441714,33.076110335459,percent_activity,1.30102999566398,28.9280863465028,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",0.955818916372114,0.836775047269216,0.731205455411378,20,cyp
NVS_ADME_hCYP2C9,"Data from the assay component NVS_ADME_hCYP2C9 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C9, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000762.2, , , ,,,Active,92.3976777898445,4.6198838894922245,5.228622401614678,0.718387279271534,2.17335298616219,76.9980648282535,percent_activity,1.30102999566398,20,,0.130088637072034,-0.460567845166298,-0.286418444650969,20,cyp
NVS_ADME_hCYP2D6,"Data from the assay component NVS_ADME_hCYP2D6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2D6, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2D6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000097.3, , , ,,,Active,80.2889464200302,4.01444732100151,4.280873753497077,0.631532420320169,2.25000991599824,66.9074553632275,percent_activity,1.30102999566398,20,,0.127817308028738,-0.458723702897488,-0.371511508331908,20,cyp
NVS_ADME_hCYP2J2,"Data from the assay component NVS_ADME_hCYP2J2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2J2, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2J2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000766.2, , , ,,,Active,109.59957156145,4.937084662467868,1.7775604274407122,0.249824373316283,3.69987482675877,91.332978259817,percent_activity,1.30102999566398,22.1992489605526,,-0.936961503489214,-1.64075409890467,-1.65294708303783,20,cyp
NVS_ADME_rCYP1A1,"Data from the assay component NVS_ADME_rCYP1A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP1A1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp1a1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_036672.2, , , ,"[57,57]",,Active,29.2622776381989,1.463113881909945,5.116782871368024,0.708996988250709,2.19248820443626,29.2244996772111,percent_activity,1.30102999566398,20,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Borderline active""]",0.750786028798544,0.6417873779285,0.589716630465563,20,cyp
NVS_ADME_rCYP2A1,"Data from the assay component NVS_ADME_rCYP2A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2A1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2a1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_036824.1, , , ,,,Active,92.0408163258528,4.60204081629264,3.7520114936292064,0.574264160094046,1.34941708254929,76.7006802721088,percent_activity,1.30102999566398,20,,-0.0474436090583678,-0.919467438643815,-0.491698363437902,20,cyp
NVS_ADME_rCYP2A2,"Data from the assay component NVS_ADME_rCYP2A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2A2, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_036825.1, , , ,,,Active,97.7091454251864,4.8854572712593205,6.569085733982028,0.817504929937835,2.91806015509037,81.424287856072,percent_activity,1.30102999566398,20,,0.381769156515694,0.0731296024805197,0.112096253599075,20,cyp
NVS_ADME_rCYP2B1,"Data from the assay component NVS_ADME_rCYP2B1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2B1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2b1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",P00176.1, , , ,,,Active,92.0538044568395,4.602690222841975,3.1999262283330707,0.505139966133288,2.57849737099665,76.7115037141136,percent_activity,1.30102999566398,20,,-0.181121689873669,-0.773905511316901,-0.671339323906327,20,cyp
NVS_ADME_rCYP2C11,"Data from the assay component NVS_ADME_rCYP2C11 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C11, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c11. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_062057.2, , , ,,,Active,93.8672921950079,4.693364609750395,0.3896010882662227,-0.409379838684194,2.09105010163613,94.551257402138,percent_activity,1.30102999566398,20,,-0.906565417476481,-1.41264023071007,-1.24550438268905,20,cyp
NVS_ADME_rCYP2C13,"Data from the assay component NVS_ADME_rCYP2C13 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C13, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c13. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_612523.1, , , ,,,Active,83.2144091933157,4.160720459665785,3.601203535568602,0.55644766785179,1.92662603349891,71.0929250263991,percent_activity,1.30102999566398,20,,0.0706829580944493,-0.538950164480849,-0.371023798566602,20,cyp
NVS_ADME_rCYP2C6,"Data from the assay component NVS_ADME_rCYP2C6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C6, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c6v1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",P05178.2, , , ,,,Active,86.9095580255871,4.345477901279355,0.5898059060612109,-0.229290882925368,1.88050923509851,89.4778108828603,percent_activity,1.30102999566398,20,,-0.470189953858916,-0.761434597750996,-0.667602552194031,20,cyp
NVS_ADME_rCYP2D1,"Data from the assay component NVS_ADME_rCYP2D1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2D1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2d1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_695225.1, , , ,,,Active,70.7971665166488,3.53985832583244,6.769279150940944,0.830542423864362,2.38012259194395,58.9976387641757,percent_activity,1.30102999566398,20,,0.510270700959257,0.0788359432641867,0.075577685003933,20,cyp
NVS_ADME_rCYP2D2,"Data from the assay component NVS_ADME_rCYP2D2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2D2, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2d2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_036862.1, , , ,,,Active,81.4229248919076,4.07114624459538,8.649143067340232,0.936973080925944,2.12024963464081,67.8524374176548,percent_activity,1.30102999566398,20,,0.662859787365759,0.334007197575533,0.400198424574164,20,cyp
NVS_ADME_rCYP3A1,"Data from the assay component NVS_ADME_rCYP3A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP3A1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp3a23/3a1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",P04800.1, , , ,,,Active,98.0890753582892,4.904453767914459,2.9190321722799117,0.465238881615845,1.20626296963301,83.3176121816467,percent_activity,1.30102999566398,20,,-0.198541808405091,-1.1244542680678,-0.60550195015426,20,cyp
NVS_ADME_rCYP3A2,"Data from the assay component NVS_ADME_rCYP3A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP3A2, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp3a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_695224.2, , , ,,,Active,97.2080842430398,4.86040421215199,0.3662934850781499,-0.436170805659155,1.1453989585559,98.1824002276446,percent_activity,1.30102999566398,20,,-0.960797154001559,-1.72038239021641,-1.28955094316868,20,cyp
NVS_ENZ_hHDAC6,"Data from the assay component NVS_ENZ_hHDAC6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hHDAC6, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene HDAC6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""hydrolase"" intended target family, where the subfamily is ""histone deacetylase"".",NP_006035.2, , , ,,,Active,30.2891332124048,1.1352624071028112,8.028183750459092,0.90461730413647,4.44671543525969,30.1737160120846,percent_activity,1.69897000433602,26.6802926115581,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",1.16068680982071,0.87397019000831,0.623371942156517,20,hydrolase
NVS_ENZ_hPDE5,"Data from the assay component NVS_ENZ_hPDE5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE5, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE5A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""phosphodiesterase"".",NP_001074.2, , , ,,,Active,48.6575342400434,2.43287671200217,6.206951741501145,0.792878368797475,2.55317680882902,40.5479452054795,percent_activity,1.69897000433602,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.583262773469532,-0.184772269117993,-0.487613386931279,20,esterase
NVS_ENZ_rCNOS,"Data from the assay component NVS_ENZ_rCNOS was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rCNOS, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Nos1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""nitric oxide synthase"".",NP_434686.1, , , ,"[32,32]",,Active,32.7577150149829,1.328307993688596,0.09440160522982591,-1.02502062078108,4.11020576184513,27.2980958634274,percent_activity,-0.698970004336019,24.6612345710708,"[""Less than 50% efficacy"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",-0.964555802885501,-1.05242335182919,-1.14430093453128,20,oxidoreductase
NVS_ENZ_rMAOAP,"Data from the assay component NVS_ENZ_rMAOAP was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOAP, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maoa. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""oxidoreductase"" intended target family, where the subfamily is ""monoamine oxidase"".",P21396.1, , , ,,,Active,39.732269179624,1.5538017097910801,20.908843621474478,1.32033001451543,4.26183394029155,33.1102243318584,percent_activity,1.69897000433602,25.5710036417493,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.67212164830885,0.876503288522147,0.0123224333241481,20,oxidoreductase
NVS_GPCR_bAdoR_NonSelective,"Data from the assay component NVS_GPCR_bAdoR_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bAdoR_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADORA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_776922.2, , , ,,,Active,48.5102040809805,2.349551562217943,9.724000022176954,0.987844951161768,3.44109665159449,40.4251700680272,percent_activity,1.69897000433602,20.6465799095669,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.795221165391859,0.147309411523484,-0.424018753263423,20,gpcr
NVS_GPCR_bH1,"Data from the assay component NVS_GPCR_bH1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bH1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HRH1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",P30546.1, , , ,,,Active,57.5603143474962,2.177186477217215,2.481926599856569,0.394788933589534,4.40632248315475,59.7234989650918,percent_activity,1.69897000433602,26.4379348989285,,0.369898172523231,0.210120747872462,0.0595255613404965,20,gpcr
NVS_GPCR_hAdoRA1,"Data from the assay component NVS_GPCR_hAdoRA1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdoRA1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADORA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_000665.1, , , ,,,Active,82.9563668711621,2.830429739834357,13.647880738720119,1.1350652187808,4.8847922103881,69.1303057287029,percent_activity,1.69897000433602,29.3087532623286,,0.921093063408525,0.590287294516027,0.357388798306518,20,gpcr
NVS_GPCR_hH1,"Data from the assay component NVS_GPCR_hH1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hH1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HRH1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_000852.1, , , ,,,Active,20.0745799201937,1.003728996009685,6.853982681599007,0.8359430027353,2.16547675294364,22.7377124483234,percent_activity,1.30102999566398,20,"[""Borderline active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.13949730881415,0.795921841855683,0.716661393928963,20,gpcr
NVS_GPCR_hOpiate_mu,"Data from the assay component NVS_GPCR_hOpiate_mu was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hOpiate_mu, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene OPRM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_000905.3, , , ,,,Active,32.165450842827,1.25751997313227,18.589804767359006,1.26927482877653,4.26308018031029,31.6237597211049,percent_activity,1.69897000433602,25.5784810818617,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.41257741768808,1.22539207684318,1.037183932467,20,gpcr
NVS_GPCR_rabPAF,"Data from the assay component NVS_GPCR_rabPAF was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rabPAF, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PTAFR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",XP_008264091.1, , , ,,,Active,85.1184979123386,3.5746535890666853,27.83177506008057,1.44454090573089,3.96861289220113,70.932081629261,percent_activity,1.69897000433602,23.8116773532068,,1.29176002918696,1.15111008362005,1.08957783745494,20,gpcr
NVS_LGIC_bGABARa1,"Data from the assay component NVS_LGIC_bGABARa1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_bGABARa1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene GABRA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",NP_001178048.1, , , ,"[10,10]",,Active,60.9862574900254,3.04931287450127,13.192078806285181,1.12031323701431,2.76732192385783,51.0791493152811,percent_activity,1.69897000433602,20,,0.858728698344455,0.446641618600996,0.319259119130949,20,ion channel
NVS_MP_hPBR,"Data from the assay component NVS_MP_hPBR was analyzed into 1 assay endpoint. This assay endpoint, NVS_MP_hPBR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene TSPO. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""cholesterol transporter"".",NP_000705.2, , , ,,,Active,38.4399940465602,1.7195761994791794,21.39324309106309,1.33027662607647,3.72572362676754,36.6433913068393,percent_activity,1.69897000433602,22.3543417606052,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.37051667560777,1.22124944989053,1.06160951508499,20,transporter
NVS_MP_rPBR,"Data from the assay component NVS_MP_rPBR was analyzed into 1 assay endpoint. This assay endpoint, NVS_MP_rPBR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Tspo. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""cholesterol transporter"".",NP_036647.1, , , ,,,Active,86.2602747548932,2.746178036844322,16.70825551145635,1.22293110810416,5.23517130581576,71.8835623116901,percent_activity,1.69897000433602,31.4110278348946,,0.993272567842497,0.603958076966271,0.317683967598987,20,transporter
NVS_NR_cAR,"Data from the assay component NVS_NR_cAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_cAR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_001009012.1, , , ,,,Active,71.5206443536457,3.5760322176822847,33.14530756967884,1.52042205337903,2.67547881471795,59.6005370053074,percent_activity,1.69897000433602,20,,0.953551681420179,0.281420235903222,0.204130271331196,20,nuclear receptor
NVS_NR_hAR,"Data from the assay component NVS_NR_hAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hAR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",, , , ,"[307,111,19,23,187,117,307,19,23,111,187,117]",,Active,53.7308171808773,2.4538244828390727,11.742490842000512,1.06976023014801,3.64946077416744,44.7756809844564,percent_activity,1.69897000433602,21.8967646450046,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.884266271811524,0.394137680568074,-0.0194285312889524,20,nuclear receptor
NVS_NR_hGR,"Data from the assay component NVS_NR_hGR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hGR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR3C1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_000167.1, , , ,"[64,66,214,71,14,318,64,214,66,71,14,318]",,Active,37.1338568164563,1.2830704735529854,19.251714896735873,1.28446942148178,4.82356679827413,30.9448818897638,percent_activity,1.69897000433602,28.9414007896448,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Less than 50% efficacy""]",1.65970785054287,1.15108628716097,0.631185506509478,20,nuclear receptor
OT_AR_ARSRC1_0960,"Data from the assay component OT_AR_ARSRC1_0960 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_AR_ARSRC1_0960, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_005408.1, , , ,,,Active,26.5263156859402,1.3263157842970101,49.72302046293996,1.69655750232167,1.6382320441989,20.4678362573099,percent_activity,2,20,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",1.97352101340691,1.33028635341496,1.15315485118308,20,nuclear receptor
Tanguay_ZF_120hpf_AXIS_up,"Data from the assay component Tanguay_ZF_120hpf_AXIS_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_AXIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,36.0369350543264,1.80184675271632,10.035064825000457,1.00152018230921,2.63537411808397,35.1968819601313,percent_activity,1.77815125038364,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.047439647646,0.737605752022431,0.544644633067722,20,malformation
Tanguay_ZF_120hpf_YSE_up,"Data from the assay component Tanguay_ZF_120hpf_YSE_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_YSE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,45.9994260700836,2.29997130350418,60.50478762920102,1.78178974091161,3.19325001944697,27.2119948774393,percent_activity,1.77815125038364,20,"[""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active""]",1.73162099246385,1.52640481695196,1.36160567861813,20,malformation
TOX21_AP1_BLA_Agonist_ch1,"Data from the assay component TOX21_AP1_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,31.370300977767,1.56851504888835,28.478499727916546,1.45451710655719,2.57591984669775,29.2870284836,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.50661678993141,1.35135343498714,1.25180924159476,20,channel 1
TOX21_AP1_BLA_Agonist_ch2,"Data from the assay component TOX21_AP1_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,56.4246077528938,2.6480429419488702,30.096606280552027,1.47851752693192,3.55134017774949,56.7124776112,percent_activity,1.90308998699194,21.3080410664969,,1.45081591287194,1.39768947697498,1.35668392049881,20,channel 2
TOX21_AP1_BLA_Agonist_ratio,"Data from the assay component TOX21_AP1_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_002219.1, , , ,,,Active,77.5096253413257,3.8754812670662853,30.64769496711759,1.48639781651493,2.7369041511147,76.3728870317,percent_activity,1.90308998699194,20,,1.42905899863096,1.37060461906123,1.36711750272255,20,dna binding
TOX21_AR_BLA_Antagonist_ratio,"Data from the assay component TOX21_AR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",, , , ,"[307,19,23,111,187,117,307,111,19,23,187,117]",,Active,93.9032692910862,3.5988686298861006,89.4195541991645,1.95143250036398,4.34874025461246,51.8746714346,percent_activity,1.90308998699194,26.0924415276748,"[""Only highest conc above baseline, active"",""Noisy data"",""Only highest conc above baseline, active"",""Noisy data""]",1.63643512858755,1.34979124383453,1.22675737885544,20,nuclear receptor
TOX21_AR_BLA_Antagonist_viability,"TOX21_AR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,39.2861228732736,1.7037079960023336,37.08312920977967,1.56917637437213,3.8431979898606,33.3469619997,percent_activity,1.90308998699194,23.0591879391636,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.62143403015417,1.4385211553199,1.24241345674975,20,cell cycle
TOX21_ARE_BLA_agonist_ratio,"Data from the assay component TOX21_ARE_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_ARE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic leucine zipper.  ",NP_006155.2, , , ,"[61,61]",[478],Active,28.3265884985221,1.416329424926105,19.076397636678383,1.28049636647809,2.50978290890691,25.6993085971,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.52786034895551,0.993687181108264,0.660243495042669,20,dna binding
TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881,"Data from the assay component TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",, , , ,,,Active,127.266193019616,3.961391769402105,24.94202022792292,1.39693162710186,5.35443940025589,100.3515316708,percent_activity,1.95424250943932,32.1266364015353,,0.92873752265306,0.562535138156406,0.44937142502435,20,nuclear receptor
TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881,"Data from the assay component TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",, , , ,"[307,111,19,23,187,117,307,19,23,111,187,117]",,Active,126.746305413273,4.241345565646723,72.3010106894695,1.85914436830133,4.98058550254545,97.0599920458,percent_activity,1.95424250943932,29.8835130152727,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.76664918734749,1.70084766618934,1.6863257755325,20,nuclear receptor
TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability,"TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,41.1293734869461,2.056468674347305,89.61337721599327,1.95237284467824,3.00006271074825,21.5355566076,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active""]",1.94591164909938,1.80269669593763,1.69393110396993,20,cell cycle
TOX21_Aromatase_Inhibition,"Data from the assay component TOX21_Aromatase_Inhibition was analyzed into 1 assay endpoint. This assay endpoint, TOX21_Aromatase_Inhibition, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP19A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.",NP_000094.2, , , ,"[122,123,7,153,25,122,123,7,153,25]",[964],Active,82.49241202808,3.0739324376234833,64.44624836062543,1.80919764063897,4.47268624701549,58.9773489292,percent_activity,1.95424250943932,26.8361174820929,,1.70318122840617,1.57104915240444,1.48985707776808,20,cyp
TOX21_CAR_Agonist_viabillity,"TOX21_CAR_Agonist_viabillity used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,91.1780967870222,4.55890483935111,92.44145900502419,1.96586679133791,2.77710640921686,40.9965425229,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.89695224289834,1.84117155801736,1.84658647509486,20,cell cycle
TOX21_CAR_Antagonist,"Data from the assay component TOX21_CAR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_CAR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1I3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_001070948.1, , , ,,,Active,90.7710515037783,3.343250660472561,77.53591013479478,1.88950288910432,4.52508953720649,67.7894479119,percent_activity,1.95424250943932,27.1505372232389,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.84327554525816,1.79514724537984,1.77022257456647,20,nuclear receptor
TOX21_CAR_Antagonist_viability,"TOX21_CAR_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,60.697585687824,3.0348792843912,54.81257065722983,1.73888017054638,2.40485484020376,57.2696908686,percent_activity,1.95424250943932,20,,1.68462041725567,1.58588053652211,1.57106663066975,20,cell cycle
TOX21_CASP3_CHO_viability,"The assay component endpoint  TOX21_CASP3_CHO_viability uses a type of viability reporter where loss-of-signal activity can be used to understand changes in viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",, , , ,,,Active,69.32984816281,3.4664924081404997,57.74409518358138,1.76150758059362,2.57636017956492,66.2967634069,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.71249760349973,1.64882528449376,1.64222725665871,20,cell cycle
TOX21_DT40,"Data from the assay component TOX21_DT40 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint.",, , , ,,,Active,90.9171316098855,3.7881162533643895,35.02363199058505,1.5443611809159,4.0001030208237,88.5745056737,percent_activity,1.95424250943932,24.0006181249422,,1.44696948409827,1.3654655207505,1.3356636131528,20,cell cycle
TOX21_DT40_100,"Data from the assay component TOX21_DT40_100 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_100, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability as they relate to the gene Ku70 - Rad54 (-/-). Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",, , , ,,,Active,101.285842311495,4.695813122970756,36.61396695149971,1.56364678519983,3.59489896137582,97.8856530328,percent_activity,1.95424250943932,21.5693937682549,,1.49268303463356,1.44816601835568,1.44436647124248,20,cell cycle
TOX21_DT40_657,"Data from the assay component TOX21_DT40_657 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_657, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene Rev3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",, , , ,,,Active,85.4151083289758,3.259867893717199,31.781929196097952,1.50218025579743,4.36700254498032,77.4214629955,percent_activity,1.95424250943932,26.2020152698819,,1.3868988847526,1.26062857137285,1.19150064506156,20,cell cycle
TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2,"Data from the assay component TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_000116.2, , , ,,,Active,59.6343948838518,2.531244410643678,59.25296125255629,1.77271005972025,3.92655318948354,41.6588629687,percent_activity,1.95424250943932,23.5593191369012,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.6665030031427,1.42329130019996,1.22501867099723,20,nuclear receptor
TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2,"Data from the assay component TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2, , , ,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,51.0545535734354,2.0840404711381484,65.84846269926084,1.8185456403605,4.08297841624554,40.3121847568,percent_activity,1.95424250943932,24.4978704974732,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.80936825575943,1.68740182861176,1.56865759651634,20,nuclear receptor
TOX21_ERb_BLA_Agonist_viability,"TOX21_ERb_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,46.0186573253434,2.2393748348884857,159.75060315492937,2.20344250655728,3.42496311979521,22.3584099184,percent_activity,1.95424250943932,20.5497787187713,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",2.05696633132455,1.35254850136023,0.703766719475236,20,cell cycle
TOX21_ERb_BLA_Antagonist_ch2,"Data from the assay component TOX21_ERb_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,71.8593685450083,1.964318789543518,77.68839298385905,1.89035613798229,6.09705587907717,55.45773112,percent_activity,1.95424250943932,36.582335274463,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.8923347484545,1.83183989530228,1.77070154467904,20,channel 2
TOX21_ERb_BLA_Antagonist_ratio,"Data from the assay component TOX21_ERb_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_001428.1, , , ,,,Active,68.4961565868358,2.824288158343789,43.10279534374767,1.63450543635558,4.04208970819059,66.2532579677,percent_activity,1.95424250943932,24.2525382491435,,1.60186875570033,1.55109043873191,1.51522511986418,20,nuclear receptor
TOX21_ERb_BLA_Antagonist_viability,"TOX21_ERb_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,47.7058512324912,2.2641642127033426,69.71462889787428,1.84332391989133,3.51166013525229,34.8453421343,percent_activity,1.95424250943932,21.0699608115137,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.81714327786084,1.70250647022214,1.59792289156625,20,cell cycle
TOX21_ERR_Antagonist,"Data from the assay component TOX21_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_004442.3, , , ,,,Active,81.6753407914482,3.865199493363107,62.660234580140305,1.79699201641019,3.52182515338437,58.0645301364,percent_activity,1.95424250943932,21.1309509203062,,1.60563106793326,1.4503815201196,1.39755461480537,20,nuclear receptor
TOX21_ERR_viability,"TOX21_ERR_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,38.6892533681607,1.934462668408035,79.72400302774066,1.90158909696789,2.25399102610353,27.5274200217,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.90526885258286,1.81732803314103,1.78230877921298,20,cell cycle
TOX21_FXR_BLA_Antagonist_ch2,"Data from the assay component TOX21_FXR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_FXR_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,45.5548326839341,1.135976946011534,86.8780029417008,1.93890982926402,6.68364982286526,48.4459413595,percent_activity,0.477121254719662,40.1018989371916,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",4.82735888272143,1.59067193456234,-1.24189853150486,20,channel 2
TOX21_FXR_BLA_antagonist_ratio,"Data from the assay component TOX21_FXR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_FXR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_001193922.1, , , ,"[27,61,27,61]",[479],Active,57.8657974472248,2.89328987236124,252.98219712837235,2.40308996006534,2.78938673282934,46.77907884935,percent_activity,0.477121254719662,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.81706868855292,0.771221910005439,0.385875347441213,20,nuclear receptor
TOX21_HRE_BLA_Agonist_viability,"TOX21_HRE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,26.4954207888243,1.324771039441215,252.98221079678484,2.4030899835299,3.0508964104962,21.0146563785,percent_activity,1.90308998699194,20,"[""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy""]",4.03116566042158,1.47786070274023,-0.777718370551791,20,cell cycle
TOX21_MMP_viability,"TOX21_MMP_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,39.5074190550025,1.975370952750125,79.2918653056418,1.89922863455485,3.32276785161468,22.1811136907,percent_activity,1.95424250943932,20,"[""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.90657994909894,1.57899621108417,1.25150759550461,20,cell cycle
TOX21_p53_BLA_p2_ch2,"Data from the assay component TOX21_p53_BLA_p2_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p2_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,35.2552909623922,1.7627645481196101,54.68015358523155,1.73782972574079,1.60204778429955,34.6125967564,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.75253101450151,1.63760673332557,1.61854859083016,20,channel 2
TOX21_p53_BLA_p2_ratio,"Data from the assay component TOX21_p53_BLA_p2_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p2_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",NP_000537.3, , , ,"[46,46]",,Active,21.861229937617,1.09306149688085,53.10769776054785,1.72515747499169,0.95929146331389,21.5447951381,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active""]",1.8540612337884,1.62274482121113,1.60587714926013,20,dna binding
TOX21_p53_BLA_p4_ch2,"Data from the assay component TOX21_p53_BLA_p4_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p4_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,26.8032499276092,1.3401624963804601,73.6633756210644,1.86725161650112,1.34760150021231,22.3360416108,percent_activity,1.95424250943932,20,"[""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.92579081278463,1.7734393643699,1.74797130274017,20,channel 2
TOX21_p53_BLA_p4_ratio,"Data from the assay component TOX21_p53_BLA_p4_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p4_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",NP_000537.3, , , ,"[46,46]",,Active,22.7406507276984,1.13703253638492,43.27658011519403,1.63625293380408,1.02079986237957,21.5530503058,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",1.85423510103045,1.43222374124799,1.39527336870343,20,dna binding
TOX21_p53_BLA_p5_ch2,"Data from the assay component TOX21_p53_BLA_p5_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p5_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,24.3228059897498,1.21614029948749,60.13358151755995,1.77911707091671,1.61374125094707,20.269005084,percent_activity,1.95424250943932,20,"[""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.94881870070246,1.62487260850484,1.53570025001528,20,channel 2
TOX21_PGC_ERR_Antagonist,"Data from the assay component TOX21_PGC_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PGC_ERR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.",NP_004442.3, , , ,,,Active,83.8738152581513,2.515627841549473,45.1549497520456,1.65470536333561,5.55685104879492,81.6495693503,percent_activity,1.95424250943932,33.3411062927695,,1.61823682086157,1.53244381981079,1.46200733253398,20,nuclear receptor
TOX21_PGC_ERR_viability,"TOX21_PGC_ERR_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,48.3319727662372,2.41659863831186,70.46582582809413,1.84797854603229,2.5904653717656,42.2735876462,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.82907266347567,1.75827776907359,1.72869804272175,20,cell cycle
TOX21_PPARd_BLA_Antagonist_ch2,"Data from the assay component TOX21_PPARd_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,151.099480179739,2.570168247892611,83.28840307915546,1.92058453526815,9.79828722001836,62.9209238426,percent_activity,1.90308998699194,58.7897233201102,"[""Borderline active"",""Only highest conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Only highest conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.89609126070565,1.84345507816222,1.80130421809629,20,channel 2
TOX21_PPARd_BLA_antagonist_ratio,"Data from the assay component TOX21_PPARd_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_006229.1, , , ,"[36,36]",,Active,79.3643845086233,2.187016140989776,36.18883111221748,1.55857455576053,6.04814805441609,77.1140366185,percent_activity,1.90308998699194,36.2888883264965,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.549267241982,1.49255422955829,1.43929122114089,20,nuclear receptor
TOX21_PPARg_BLA_antagonist_ratio,"Data from the assay component TOX21_PPARg_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_056953.2, , , ,"[34,36,58,72,163,72,36,58,34,163]",,Active,49.0264779626111,1.3625215711147969,33.504956518998576,1.52510905866736,5.9970277415496,46.7796282633,percent_activity,1.90308998699194,35.9821664492976,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.59963277825694,1.48506238380867,1.36373133142963,20,nuclear receptor
TOX21_PR_BLA_Antagonist_ch2,"Data from the assay component TOX21_PR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,64.9621255571773,1.5636570749686198,54.75266708271752,1.7384052791486,6.92416585421295,63.4041695414,percent_activity,1.95424250943932,41.5449951252777,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.76952849139004,1.69742621683229,1.61912464903339,20,channel 2
TOX21_PR_BLA_Antagonist_ratio,"Data from the assay component TOX21_PR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity an be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000917.3, , , ,,,Active,74.2701662257723,3.713508311288615,51.63001073184339,1.71290221531993,2.51198214229767,70.9943591909,percent_activity,1.95424250943932,20,,1.63812068978058,1.54951403315574,1.54830110284829,20,nuclear receptor
TOX21_PXR_Agonist,"Data from the assay component TOX21_PXR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PXR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is non-steroidal.",NP_071285.1, , , ,,,Active,100.070001012423,5.003500050621151,32.489492011415,1.51174292099829,1.80636679455099,67.5809077389,percent_activity,1.60205999132796,20,,1.3600084000405,1.19887474908381,1.27140102985174,20,nuclear receptor
TOX21_PXR_viability,"The assay component endpoint  TOX21_PXR_viability was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",, , , ,,,Active,33.1352008022854,1.65676004011427,60.60335429409547,1.78249666230327,2.43196946437473,31.2115671531,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.80532913173307,1.71382151352794,1.6631729226187,20,cell cycle
TOX21_RAR_LUC_Antagonist,"Data from the assay component TOX21_RAR_LUC_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RAR_LUC_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RARA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where subfamily is non-steroidal.",NP_000955.1, , , ,,,Active,57.7708260051284,1.9416156071915347,47.40379029843343,1.6758130682539,4.95899959044,56.0050735783,percent_activity,1.95424250943932,29.75399754264,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.67907886225697,1.61832813368645,1.55653275315664,20,nuclear receptor
TOX21_RT_HEK293_FLO_16hr_viability,"TOX21_RT_HEK293_FLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,33.8040679030642,1.34802292700724,0.08254174373084136,-1.08332636069869,4.17946253309319,28.1700565951,percent_activity,-1,25.0767751985591,"[""Less than 50% efficacy"",""Borderline active"",""Cell viability assay fit with gnls winning model"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Cell viability assay fit with gnls winning model"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",-1.02602734260873,-1.11200605939793,-1.20260667437905,20,cell cycle
TOX21_RT_HEK293_FLO_32hr_viability,"TOX21_RT_HEK293_FLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,37.510266907806,1.3193940912962607,0.08225753964559429,-1.08482428454629,4.73831980341741,31.2585558882,percent_activity,-1,28.4299188205045,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Only one conc above baseline, active"",""Cell viability assay fit with gnls winning model"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Borderline active"",""Cell viability assay fit with gnls winning model"",""Less than 50% efficacy""]",-1.02286514414673,-1.11163963753237,-1.20410459840514,20,cell cycle
TOX21_RT_HEK293_FLO_40hr_viability,"TOX21_RT_HEK293_FLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,30.9148151524621,1.0832862896620115,30.927312661669777,1.49034218489448,4.75633195144065,32.0106364606,percent_activity,-1,28.5379917086439,"[""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy""]",3.87052965467095,1.34279851756725,-0.613808580114427,20,cell cycle
TOX21_RT_HEK293_GLO_08hr_viability,"TOX21_RT_HEK293_GLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,42.8262014819765,1.7639342790440402,29.58743990828547,1.47110738889146,4.04646609105207,42.7531725228,percent_activity,1.90308998699194,24.2787965463124,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.48572541138271,1.42076300127439,1.35182689372207,20,cell cycle
TOX21_RT_HEK293_GLO_16hr_viability,"TOX21_RT_HEK293_GLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,44.5682455451326,1.8488251751855862,32.90120083461841,1.51721174920624,4.0177086637968,44.4446294958,percent_activity,1.90308998699194,24.1062519827808,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.5279575367457,1.45214899873969,1.37315674182728,20,cell cycle
TOX21_RT_HEK293_GLO_24hr_viability,"TOX21_RT_HEK293_GLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,34.4393349342003,1.4036724707395523,34.536987395573924,1.53828445209248,4.08919407864135,33.7303858667,percent_activity,1.90308998699194,24.5351644718481,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.62399393064073,1.48236444374374,1.33068629012667,20,cell cycle
TOX21_RT_HEK293_GLO_32hr_viability,"TOX21_RT_HEK293_GLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,45.8482336435829,1.8249942564509056,35.769202595111565,1.55350925850505,4.18706647811088,45.7703890979,percent_activity,1.90308998699194,25.1223988686653,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.56395289298576,1.50060375902619,1.43422894356879,20,cell cycle
TOX21_RT_HEK293_GLO_40hr_viability,"TOX21_RT_HEK293_GLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,52.1653682815605,2.09454267185228,35.880244857654105,1.5548553981392,4.15089564121323,52.0797118242,percent_activity,1.90308998699194,24.9053738472794,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.54995131062103,1.49189712641988,1.43557507685228,20,cell cycle
TOX21_RT_HEPG2_FLO_32hr_ctrl_viability,"TOX21_RT_HEPG2_FLO_32hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,30.8355830145435,1.0531003963667145,54.66324076877852,1.73769537573344,4.88012714978376,29.4372575634,percent_activity,1.90308998699194,29.2807628987026,"[""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.89705877678466,1.73221610869791,1.61841459693833,20,cell cycle
TOX21_RT_HEPG2_FLO_40hr_ctrl_viability,"TOX21_RT_HEPG2_FLO_40hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,47.8027068651311,1.7751664994599627,43.94938592041163,1.64295281130422,4.48809608184861,47.4092001348,percent_activity,1.90308998699194,26.9285764910917,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.65677843759243,1.59212819737284,1.52367249141859,20,cell cycle
TOX21_SBE_BLA_Antagonist_ratio,"Data from the assay component TOX21_SBE_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor receptor intended target family, where subfamily is transforming growth factor beta.",NP_005891.1, , , ,,,Active,52.1719412473061,2.5571437187797064,76.12312173738196,1.88151658998702,3.40040470833105,29.9431275423,percent_activity,1.90308998699194,20.4024282499863,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.85747549290698,1.80472972997999,1.76223622768456,20,growth factor receptor
TOX21_SHH_3T3_GLI3_Agonist_viability,"TOX21_SHH_3T3_GLI3_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,105.145613995408,5.2572806997704,70.23175279943652,1.84653350739712,2.74374658540332,75.7662914926,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Cell viability assay fit with gnls winning model"",""Only highest conc above baseline, active"",""Cell viability assay fit with gnls winning model""]",1.7082373570703,1.61112273007379,1.63677147723613,20,cell cycle
TOX21_SHH_3T3_GLI3_Antagonist,"Data from the assay component TOX21_SHH_3T3_GLI3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SHH_3T3_GLI3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GLI3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.",, , , ,,,Active,78.3177232840665,1.7718044570681577,46.511215720752205,1.66755769134798,7.36703975915985,64.3835791281,percent_activity,1.95424250943932,44.2022385549591,,1.7077113550836,1.52283439841401,1.3269460179196,20,dna binding
TOX21_SHH_3T3_GLI3_Antagonist_viability,"TOX21_SHH_3T3_GLI3_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,32.4895891370074,1.62447945685037,76.42695311754858,1.8832465460875,2.48726544475101,26.4431201518,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.90880677689718,1.81754915023832,1.76396623084357,20,cell cycle
TOX21_TR_LUC_GH3_Antagonist,"Data from the assay component TOX21_TR_LUC_GH3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.","NP_003241.2|NP_000452.2", , , ,,,Active,130.293209484696,5.80713570534771,99.60855087132782,1.99829662192603,3.73945711206963,53.9228396578,percent_activity,1.95424250943932,22.4367426724178,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.78735962384453,1.68094434403871,1.70310807502088,20,nuclear receptor
TOX21_VDR_BLA_antagonist_ratio,"Data from the assay component TOX21_VDR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_VDR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP24A1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.","NP_000773.2|NP_000367.1", , , ,,,Active,127.275208386467,2.848981409843764,83.2620067642069,1.9204468739555,7.44565572024603,57.7239252058,percent_activity,1.90308998699194,44.6739343214762,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.88704368406462,1.83636599440522,1.80103564298538,20,nuclear receptor
UKN2_HCS_IMR90_cell_viability_dn,"The assay endpoint UKN2_HCS_IMR90_cell_viability_dn was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is viability.",, , , ,,,Active,118.96412188480653,4.719370263851342,33.485766255581,1.5248602413568038,5.041525255860019,96.3136985705475,percent_activity,1.77815125038364,25.207626279300097,,1.263900401576072,1.142123212214027,1.0883443370743304,20.00040054321289,cell cycle
UKN2_HCS_IMR90_neural_migration_dn,"The assay endpoint UKN2_HCS_IMR90_neural_migration_dn was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is neural crest cell migration.",, , , ,,,Active,96.25814543117394,1.5836961600717843,19.47503566784466,1.2894782617404394,12.156138009049773,97.41847826086956,percent_activity,1.77815125038364,60.78069004524886,,1.3187049397373147,1.2626395161561659,1.1701978153053687,20.00040054321289,neurodevelopment
UKN4_HCS_LUHMES_cell_viability_dn,"The assay endpoint UKN4_HCS_LUHMES_cell_viability_dn was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is viability.",, , , ,,,Active,73.86535872954862,2.9546143491819445,21.810816897659944,1.3386719318557334,0.7078846407831513,25.214754287145535,percent_activity,1.30102999566398,25,"[""Borderline active"",""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.3022885896785101,1.1475822258679667,1.2193893007971637,20.00040054321289,cell cycle
UKN4_HCS_LUHMES_neurite_outgrowth_dn,"The assay endpoint UKN4_HCS_LUHMES_neurite_outgrowth_dn was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is neurite outgrowth.",, , , ,,,Active,69.93393382853529,2.7973573531414115,10.263991015801448,1.0113162632236956,8.469355519709685,70.87523059422847,percent_activity,1.30102999566398,25,"[""Only one conc above baseline, active"",""Noisy data""]",0.9794332628877381,0.9808097891625583,0.8918347228769705,20.00040054321289,neurodevelopment
UKN5_HCS_SBAD2_cell_viability_dn,"The assay endpoint UKN5_HCS_SBAD2_cell_viability_dn was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is viability.",, , , ,,,Active,75.47536314571485,3.019014525828594,43.52094515742338,1.6386983184961035,3.4397263053001415,57.135708084297654,percent_activity,1.77815125038364,25,"[""Only one conc above baseline, active""]",1.5506130857085325,1.4076710350159949,1.3632351642815759,20.00040054321289,cell cycle
UKN5_HCS_SBAD2_neurite_outgrowth_dn,"The assay endpoint UKN5_HCS_SBAD2_neurite_outgrowth_dn was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is neurite outgrowth.",, , , ,,,Active,114.53804639620056,3.8449463074711754,33.242888097093854,1.521698747667555,5.957848939197922,92.73220401286791,percent_activity,1.77815125038364,29.789244695989613,,1.3355145553723076,1.2211233652398503,1.1304302721170936,20.00040054321289,neurodevelopment
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist,"Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist was analyzed into 1 assay endpoint. 
This assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist, was analyzed in the positive fitting direction relative to DHT as the baseline of activity. 
Using a type of binding reporter, measures of receptor for loss-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.",, , , ,,,Active,99.6686442693607,2.62440667485624,35.13128755881328,1.54569406694092,12.6591971211703,80.1708842180143,percent_activity,2,37.9775913635109,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.26864196246868,1.26864196246868,0.290917305228105,20.00040054321289,nuclear receptor
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist,"Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist was analyzed into 1 assay endpoint. 
This assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist, was analyzed in the positive fitting direction relative to DHT as the baseline of activity. 
Using a type of binding reporter, measures of receptor for loss-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.",, , , ,,,Active,84.3522464396785,1.3279297100082723,34.467320964417034,1.53740752838658,21.1738733368031,84.3280746667918,percent_activity,2,63.5216200104093,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.59793753541059,1.59793753541059,1.41812208571819,20.00040054321289,nuclear receptor